Talphera (TLPH) EBT Margin Growth (1y) (2012 - 2022)
Powered by 
Analysis
Talphera (TLPH) EBT Margin Growth (1y) (2012 - 2022) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 1,045.00 |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -16,571.00 |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | -153.00 |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | -571.00 |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 553.00 |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 4,709.00 |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 1,911.00 |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -2,328.00 |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -801,907.00 |
| 10 | Talphera | 92.90 Mn | 92.90 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2022 | -20,903.00 |
| Dec 31, 2021 | -39.46 Mn |
| Sep 30, 2021 | 20,299.00 |
| Jun 30, 2021 | -199,679.00 |
| Mar 31, 2021 | 243,837.00 |
| Dec 31, 2020 | 182,802.00 |
| Sep 30, 2020 | 144,114.00 |
| Jun 30, 2020 | 109,292.00 |
| Mar 31, 2020 | 20,954.00 |
| Dec 31, 2019 | -98,781.00 |
| Sep 30, 2019 | 121,059.00 |
| Jun 30, 2019 | -3,032.00 |
| Mar 31, 2019 | -199,498.00 |
| Dec 31, 2018 | -61,780.00 |
| Sep 30, 2018 | -242,939.00 |
| Jun 30, 2018 | -79,734.00 |
| Mar 31, 2018 | -205,841.00 |
| Dec 31, 2017 | -128,035.00 |
| Sep 30, 2017 | -53,531.00 |
| Jun 30, 2017 | -24,625.00 |